Research programme: antibody drug conjugates - ADC Therapeutics

Drug Profile

Research programme: antibody drug conjugates - ADC Therapeutics

Alternative Names: ADCT 501; ADCT 601

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADC Therapeutics; Cancer Research Technology
  • Class Immunoconjugates
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 27 Oct 2017 Preclinical trials in Solid tumours (Metastatic disease) in United Kingdom before October 2017 (ADC Therapeutics pipeline, October 2017)
  • 23 Oct 2017 ADC Therapeutics announces intention to submit INDs for ADCT 601 within 18 months
  • 05 Jan 2017 Preclinical trials in Multiple myeloma in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top